Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
59,119,327
-
Total 13F shares
-
53,011,338
-
Share change
-
+794,586
-
Total reported value
-
$1,384,693,451
-
Put/Call ratio
-
92%
-
Price per share
-
$26.13
-
Number of holders
-
180
-
Value change
-
+$27,801,917
-
Number of buys
-
104
-
Number of sells
-
80
Institutional Holders of Vanda Pharmaceuticals Inc. - Common Stock (VNDA) as of Q4 2018
As of 31 Dec 2018,
Vanda Pharmaceuticals Inc. - Common Stock (VNDA) was held by
180 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,011,338 shares.
The largest 10 holders included
BlackRock Inc., Consonance Capital Management LP, Vanguard Group Inc, Palo Alto Investors LP, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, MACQUARIE GROUP LTD, ADAGE CAPITAL PARTNERS GP, L.L.C., GLENMEDE TRUST CO NA, and FMR LLC.
This page lists
180
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.